Viking Therapeutics, Inc.

VKTXReported to SECin USCIK 0001607678Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 8. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 8
Form 4 lines at Viking Therapeutics, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Kelly-Gemmell Dorothy Elizabeth—Awardnothing paid40,800 sharesAug 7, 2026Kelly-Gemmell Dorothy Elizabethnothing paidAward · Aug 7Award40,800Aug 7, 2026
Kelly-Gemmell Dorothy Elizabeth—Awardnothing paid6,333 sharesAug 7, 2026Kelly-Gemmell Dorothy Elizabethnothing paidAward · Aug 7Award6,333Aug 7, 2026
Lian BrianPresident & CEOOpen-market sell$4,947,888148,517 sharesJul 29, 2026Lian BrianPresident & CEO$4,947,888Sell · Jul 29Open-market sell148,517Jul 29, 2026
Lian BrianPresident & CEOAwardnothing paid221,667 sharesJul 29, 2026Lian BrianPresident & CEOnothing paidAward · Jul 29Award221,667Jul 29, 2026
ZANTE GREGChief Financial OfficerOpen-market sell$710,14121,217 sharesJul 29, 2026ZANTE GREGChief Financial Officer$710,141Sell · Jul 29Open-market sell21,217Jul 29, 2026